|Bid||2.05 x 1800|
|Ask||2.09 x 800|
|Day's Range||2.0000 - 2.0700|
|52 Week Range||1.1500 - 7.9500|
|Beta (3Y Monthly)||4.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
Conatus Pharmaceuticals Inc. (CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. “With screening in the ENCORE-LF clinical trial complete, we remain on track for clinical events as announced last quarter, with top-line results expected in mid-2019,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development at Conatus. The ENCORE-LF clinical trial is designed to evaluate safety, dosing and efficacy of emricasan in patients with decompensated NASH cirrhosis as an integral part of the company’s initial registration strategy.
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.
SAN DIEGO, Jan. 28, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s.
Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
Shares of Conatus Pharmaceuticals Inc. plummeted 53% Thursday after the company announced its Phase 2 clinical trial of emricasan did not meet its primary endpoint. Patients with liver damage from nonalcoholic fatty liver disease did not show sufficient patient improvement on the drug compared to a placebo. Stifel analysts downgraded the company to hold from buy and lowered their price target to $4 from $10, while analysts at SunTrust Robinson Humphrey lowered their price target to $12 from $20. Friday's selloff puts the biotech's stock on track to suffer its biggest one-day percentage decline since the company went public in July 2013. Shares of Conatus have fallen 53% in the year to date, and the S&P 500 has fallen 0.1%.
NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, ...
Conatus Pharmaceuticals Inc’s (NASDAQ:CNAT): Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. With Read More...
Investors need to pay close attention to Conatus (CNAT) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Conatus Pharmaceuticals and Titan Pharmaceuticals were both seeing gains in Friday’s trading session. There was no news to explain Titan shares jumping but Conatus reported third quarter results and an update on its trials last week. Conatus Pharmaceuticals Inc. shares closed up 19.63% on about 1.8 million shares traded on Friday.
Conatus (CNAT) delivered earnings and revenue surprises of 0.00% and -20.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 15 cents per share. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also ...